X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Viking investigational product VK2735, which is a Dual GLP-1/GIP Receptor Agonist. Currently, it is being evaluated in the phase I clinical trial studies for the treatment related to obesity.
Lead Product(s): VK2735
Therapeutic Area: Nutrition and Weight Loss Product Name: VK2735
Highest Development Status: Phase IProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 26, 2024
Details:
The net proceeds from the offering for continued development of its VK2809, a small molecule selective thyroid hormone receptor beta agonist. It is currently being evaluated in a Phase 2b study for for the treatment of non-alcoholic steatohepatitis and fibrosis.
Lead Product(s): VK2809
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: VK2809
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Morgan Stanley
Deal Size: $632.5 million Upfront Cash: Undisclosed
Deal Type: Public Offering March 04, 2024
Details:
The net proceeds from the offering for continued development of its VK2809, a small molecule selective thyroid hormone receptor beta agonist. It is currently being evaluated in a Phase 2b study for for the treatment of non-alcoholic steatohepatitis and fibrosis.
Lead Product(s): VK2809
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: VK2809
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Morgan Stanley
Deal Size: $550.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 28, 2024
Details:
The net proceeds from the proposed offering for continued development of its VK2809, small molecule selective thyroid hormone receptor beta agonist. It is being evaluated in clinical studies for the treatment of non-alcoholic steatohepatitis and fibrosis.
Lead Product(s): VK2809
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: VK2809
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Morgan Stanley
Deal Size: $350.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 27, 2024
Details:
VK2809 novel liver-selective thyroid hormone receptor beta agonist,which is being evaluated for the treatment of patients with biopsy-confirmed non-alcoholic steatohepatitis.
Lead Product(s): VK2809
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: VK2809
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 13, 2023
Details:
VK2735 is a novel dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors for the potential treatment of obesity and various metabolic disorders.
Lead Product(s): VK2735
Therapeutic Area: Nutrition and Weight Loss Product Name: VK2735
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 23, 2023
Details:
VK2735 is a novel dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors for the potential treatment of obesity and various metabolic disorders.
Lead Product(s): VK2735
Therapeutic Area: Nutrition and Weight Loss Product Name: VK2735
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 06, 2023
Details:
VK2809 is an orally available, selective agonist of the thyroid beta receptor, suggesting promising therapeutic potential in a range of lipid disorders. Drug is currently being evaluated for biopsy-confirmed non-alcoholic steatohepatitis.
Lead Product(s): VK2809
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: VK2809
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 16, 2023
Details:
VK2735 is a novel dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors for the potential treatment of various metabolic disorders.
Lead Product(s): VK2735
Therapeutic Area: Nutrition and Weight Loss Product Name: VK2735
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 28, 2023
Details:
VK2735 is a novel dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors for the potential treatment of various metabolic disorders.
Lead Product(s): VK2735
Therapeutic Area: Nutrition and Weight Loss Product Name: VK2735
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 28, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
